<p>Caxton Associates LLP 在第二季度购买了 Arvinas, Inc. (NASDAQ:ARVN - 免费报告) 的新股份，根据其最近向 SEC 提交的 13F 文件。该公司购买了 298,062 股，价值约为 2,194,000 美元。Caxton Associates LLP 在最近的报告期末持有 Arvinas 0.41% 的股份。</p>
<ul>
<li>3 只小型生物制药股票，2023 年可能会实现大幅增长</li>
</ul>
<p>其他一些对冲基金和机构投资者也增加或减少了在该公司的股份。先锋集团在第一季度将其在 Arvinas 的股份增加了 18.4%。先锋集团现在拥有 8,362,200 股，价值 58,703,000 美元，在此期间又购买了 1,299,639 股。德意志银行在第一季度将其在 Arvinas 的持股增加了 5.3%。德意志银行现在拥有 228,633 股，价值 1,605,000 美元，在上个季度又购买了 11,413 股。景顺公司在第一季度将其在 Arvinas 的持仓增加了 119.4%。景顺公司现在拥有 81,747 股，价值 574,000 美元，在此期间又购买了 44,493 股。Nuveen LLC 在第一季度获得了 Arvinas 的新股份，价值 1,170,000 美元。最后，拉塞尔投资集团在第一季度将其在 Arvinas 的股份增加了 444.8%。拉塞尔投资集团现在拥有 41,549 股，价值 292,000 美元，在上个季度又购买了 33,922 股。95.19% 的股票由机构投资者持有。</p>
<h2>Arvinas 的内部活动</h2>
<p>在相关消息中，董事 Briggs Morrison 于 9 月 22 日星期一购买了 30,000 股公司的股票。每股平均成本为 7.57 美元，总价值为 227,100.00 美元。收购后，该董事持有 76,021 股，价值 575,478.97 美元。这代表了他们持股的 65.19% 的增长。该收购在向 SEC 提交的文件中披露，可以通过此超链接访问。4.73% 的股票由内部人士持有。</p>
<h2>分析师的升级和降级</h2>
<p>ARVN 已成为多份分析师报告的主题。高盛集团在 10 月 15 日的报告中重申了对 Arvinas 的 “卖出” 评级，并将目标价设定为 6.00 美元（从 8.00 美元下调）。Weiss Ratings 在 12 月 9 日的研究报告中重申了对 Arvinas 的 “卖出（d-）” 评级。富国银行在 11 月 6 日的报告中将 Arvinas 的目标价从 16.00 美元下调至 15.00 美元，并对该公司给予 “增持” 评级。巴克莱在 11 月 6 日的研究报告中将 Arvinas 的目标价从 15.00 美元上调至 16.00 美元，并给予该股票 “增持” 评级。最后，美国银行在 9 月 24 日的研究报告中将 Arvinas 的评级从 “买入” 下调至 “中性”，并将目标价设定为 10.00 美元。根据 MarketBeat 的数据，11 位分析师对该股票给予 “买入” 评级，10 位给予 “持有” 评级，2 位给予 “卖出” 评级。目前，Arvinas 的平均评级为 “持有”，共识目标价为 16.39 美元。</p>
<p><strong>查看我们关于 ARVN 的最新研究报告</strong></p>
<h2>Arvinas 股票上涨 0.1%</h2>
<p>NASDAQ ARVN 的股票在周一开盘时为 12.58 美元。该公司的市值为 8.0789 亿美元，市盈率为-15.53，贝塔值为 2.44。该股票的 50 日移动平均价格为 10.80 美元，200 日移动平均价格为 8.74 美元。Arvinas, Inc. 的 12 个月低点为 5.90 美元，12 个月高点为 21.00 美元。</p>
<p>Arvinas (NASDAQ:ARVN - 获取免费报告) 最近于 11 月 5 日发布了季度财报。该公司报告本季度每股收益为（0.48 美元），超出分析师一致预期的（0.75 美元）0.27 美元。Arvinas 的股本回报率为-9.77%，净利润率为-18.73%。该公司在本季度的收入为 4,190 万美元，而一致预期为 2,936 万美元。去年同期，该公司每股收益为（0.68 美元）。Arvinas 的收入同比下降了 59.1%。整体来看，研究分析师预计 Arvinas, Inc. 本财年的每股收益将为-3.81。</p>
<p>Arvinas 宣布其董事会已于 9 月 17 日批准了一项股票回购计划，授权公司回购 1 亿美元的流通股份。该回购授权允许公司通过公开市场购买最多 17.9% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>Arvinas 公司简介</h2>
<p>(免费报告)</p>
<p>Arvinas, Inc. 是一家临床阶段的生物技术公司，专注于发现、开发和商业化降解致病蛋白的疗法。该公司设计了蛋白质降解剂（PROTAC），旨在利用身体自身的自然蛋白质处理系统来降解和去除致病蛋白。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Arvinas</li>
<li>想在下跌趋势中获利？下跌趋势的解释。</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了实施阶段</li>
<li>股票市场行业：它们是什么，有多少种？</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><strong>想看看其他对冲基金持有的 ARVN 吗？</strong> 访问 HoldingsChannel.com 获取 Arvinas, Inc. (NASDAQ:ARVN - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Arvinas 吗？</h2>
<p>在考虑 Arvinas 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arvinas 并不在名单上。</p>
<p>虽然 Arvinas 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ARVN

<p>Caxton Associates LLP 收购了 298,062 股 Arvinas, Inc. 的股票，价值 219 万美元，持有该公司 0.41% 的股份。其他机构投资者也调整了他们的持股。分析师对 Arvinas 的评级褒贬不一，普遍目标价为 16.39 美元。Arvinas 报告的季度收益好于预期，收入同比下降 59.1%。该公司宣布了一项股票回购计划</p>

<p>Caxton Associates LLP bought a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 298,062 shares of the company's stock, valued at approximately $2,194,000. Caxton Associates LLP owned 0.41% of Arvinas at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Caxton Associates LLP 在第二季度购买了 Arvinas, Inc. (NASDAQ:ARVN - 免费报告) 的新股份，根据其最近向 SEC 提交的 13F 文件。该公司购买了 298,062 股，价值约为 2,194,000 美元。Caxton Associates LLP 在最近的报告期末持有 Arvinas 0.41% 的股份。</p>
</div><ul>
<li>3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型生物制药股票，2023 年可能会实现大幅增长</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Arvinas by 18.4% in the first quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock valued at $58,703,000 after acquiring an additional 1,299,639 shares during the period. Deutsche Bank AG lifted its holdings in shares of Arvinas by 5.3% in the 1st quarter. Deutsche Bank AG now owns 228,633 shares of the company's stock worth $1,605,000 after purchasing an additional 11,413 shares in the last quarter. Invesco Ltd. grew its position in Arvinas by 119.4% in the 1st quarter. Invesco Ltd. now owns 81,747 shares of the company's stock valued at $574,000 after purchasing an additional 44,493 shares during the period. Nuveen LLC acquired a new stake in Arvinas in the 1st quarter valued at $1,170,000. Finally, Russell Investments Group Ltd. increased its stake in Arvinas by 444.8% during the 1st quarter. Russell Investments Group Ltd. now owns 41,549 shares of the company's stock valued at $292,000 after purchasing an additional 33,922 shares in the last quarter. 95.19% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也增加或减少了在该公司的股份。先锋集团在第一季度将其在 Arvinas 的股份增加了 18.4%。先锋集团现在拥有 8,362,200 股，价值 58,703,000 美元，在此期间又购买了 1,299,639 股。德意志银行在第一季度将其在 Arvinas 的持股增加了 5.3%。德意志银行现在拥有 228,633 股，价值 1,605,000 美元，在上个季度又购买了 11,413 股。景顺公司在第一季度将其在 Arvinas 的持仓增加了 119.4%。景顺公司现在拥有 81,747 股，价值 574,000 美元，在此期间又购买了 44,493 股。Nuveen LLC 在第一季度获得了 Arvinas 的新股份，价值 1,170,000 美元。最后，拉塞尔投资集团在第一季度将其在 Arvinas 的股份增加了 444.8%。拉塞尔投资集团现在拥有 41,549 股，价值 292,000 美元，在上个季度又购买了 33,922 股。95.19% 的股票由机构投资者持有。</p>
</div><h2>Insider Activity at Arvinas</h2>
<div class="lb-trans"><h2>Arvinas 的内部活动</h2>
</div><p>In related news, Director Briggs Morrison purchased 30,000 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The shares were bought at an average cost of $7.57 per share, with a total value of $227,100.00. Following the acquisition, the director owned 76,021 shares of the company's stock, valued at $575,478.97. This represents a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.73% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Briggs Morrison 于 9 月 22 日星期一购买了 30,000 股公司的股票。每股平均成本为 7.57 美元，总价值为 227,100.00 美元。收购后，该董事持有 76,021 股，价值 575,478.97 美元。这代表了他们持股的 65.19% 的增长。该收购在向 SEC 提交的文件中披露，可以通过此超链接访问。4.73% 的股票由内部人士持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>ARVN has been the subject of a number of analyst reports. The Goldman Sachs Group reiterated a &#34;sell&#34; rating and set a $6.00 price objective (down from $8.00) on shares of Arvinas in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Arvinas in a research report on Tuesday, December 9th. Wells Fargo &amp; Company decreased their price objective on Arvinas from $16.00 to $15.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, November 6th. Barclays increased their price objective on Arvinas from $15.00 to $16.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, November 6th. Finally, Bank of America cut Arvinas from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $10.00 target price on the stock. in a research report on Wednesday, September 24th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, Arvinas presently has an average rating of &#34;Hold&#34; and a consensus target price of $16.39.</p>
<div class="lb-trans"><p>ARVN 已成为多份分析师报告的主题。高盛集团在 10 月 15 日的报告中重申了对 Arvinas 的 “卖出” 评级，并将目标价设定为 6.00 美元（从 8.00 美元下调）。Weiss Ratings 在 12 月 9 日的研究报告中重申了对 Arvinas 的 “卖出（d-）” 评级。富国银行在 11 月 6 日的报告中将 Arvinas 的目标价从 16.00 美元下调至 15.00 美元，并对该公司给予 “增持” 评级。巴克莱在 11 月 6 日的研究报告中将 Arvinas 的目标价从 15.00 美元上调至 16.00 美元，并给予该股票 “增持” 评级。最后，美国银行在 9 月 24 日的研究报告中将 Arvinas 的评级从 “买入” 下调至 “中性”，并将目标价设定为 10.00 美元。根据 MarketBeat 的数据，11 位分析师对该股票给予 “买入” 评级，10 位给予 “持有” 评级，2 位给予 “卖出” 评级。目前，Arvinas 的平均评级为 “持有”，共识目标价为 16.39 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on ARVN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ARVN 的最新研究报告</strong></p>
</div><h2>Arvinas Stock Up 0.1%</h2>
<div class="lb-trans"><h2>Arvinas 股票上涨 0.1%</h2>
</div><p>Shares of NASDAQ ARVN opened at $12.58 on Monday. The company has a market capitalization of $807.89 million, a PE ratio of -15.53 and a beta of 2.44. The stock's 50 day moving average price is $10.80 and its 200-day moving average price is $8.74. Arvinas, Inc. has a twelve month low of $5.90 and a twelve month high of $21.00.</p>
<div class="lb-trans"><p>NASDAQ ARVN 的股票在周一开盘时为 12.58 美元。该公司的市值为 8.0789 亿美元，市盈率为-15.53，贝塔值为 2.44。该股票的 50 日移动平均价格为 10.80 美元，200 日移动平均价格为 8.74 美元。Arvinas, Inc. 的 12 个月低点为 5.90 美元，12 个月高点为 21.00 美元。</p>
</div><p>Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.27. Arvinas had a negative return on equity of 9.77% and a negative net margin of 18.73%.The company had revenue of $41.90 million during the quarter, compared to the consensus estimate of $29.36 million. During the same period last year, the business posted ($0.68) earnings per share. Arvinas's revenue was down 59.1% on a year-over-year basis. As a group, research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Arvinas (NASDAQ:ARVN - 获取免费报告) 最近于 11 月 5 日发布了季度财报。该公司报告本季度每股收益为（0.48 美元），超出分析师一致预期的（0.75 美元）0.27 美元。Arvinas 的股本回报率为-9.77%，净利润率为-18.73%。该公司在本季度的收入为 4,190 万美元，而一致预期为 2,936 万美元。去年同期，该公司每股收益为（0.68 美元）。Arvinas 的收入同比下降了 59.1%。整体来看，研究分析师预计 Arvinas, Inc. 本财年的每股收益将为-3.81。</p>
</div><p>Arvinas announced that its Board of Directors has approved a stock repurchase program on Wednesday, September 17th that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 17.9% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued.</p>
<div class="lb-trans"><p>Arvinas 宣布其董事会已于 9 月 17 日批准了一项股票回购计划，授权公司回购 1 亿美元的流通股份。该回购授权允许公司通过公开市场购买最多 17.9% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>Arvinas Company Profile</h2>
<div class="lb-trans"><h2>Arvinas 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.</p>
<div class="lb-trans"><p>Arvinas, Inc. 是一家临床阶段的生物技术公司，专注于发现、开发和商业化降解致病蛋白的疗法。该公司设计了蛋白质降解剂（PROTAC），旨在利用身体自身的自然蛋白质处理系统来降解和去除致病蛋白。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Arvinas</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>What is a Bond Market Holiday? How to Invest and Trade</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Arvinas</li>
<li>想在下跌趋势中获利？下跌趋势的解释。</li>
<li>Dave &amp; Buster’s 的反转在双底突破后进入了实施阶段</li>
<li>股票市场行业：它们是什么，有多少种？</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>债券市场假期是什么？如何投资和交易</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ARVN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 ARVN 吗？</strong> 访问 HoldingsChannel.com 获取 Arvinas, Inc. (NASDAQ:ARVN - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJWTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ARVN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arvinas Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arvinas 吗？</h2>
</div><p>Before you consider Arvinas, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Arvinas 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Arvinas 并不在名单上。</p>
</div><p>While Arvinas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arvinas 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Caxton Associates LLP 在 Arvinas, Inc. $ARVN 中建立了价值 219 万美元的头寸